Why Bloom Energy Stock Is Powering Higher This Week
Bloom Energy reported a new deal with Oracle last week.
An analyst upwardly revised the price target on Bloom Energy stock.
The company continues to report growing revenue and earnings before interest, taxes, depreciaiton, and amortization.
10 stocks we like better than Bloom Energy ›
Soaring 43.6% from the start of July through the end of trading last week, the stock of Bloom Energy (NYSE: BE) has been red hot this month. And the trend seems to be continuing through the remainder of the month.
Although the company didn't have any news to report that explains the fuel cell maker's rise this week, it's clear that the market's appetite for Bloom Energy remains strong.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
According to data provided by S&P Global Market Intelligence, shares have risen 9.2% from the end of last Friday's session through 2:05 p.m. ET today.
Bloom is blossoming in investors' eyes thanks to this opportunity
Investors leaped at the opportunity to power their portfolios with the stock last week after the company announced a deal with Oracle for the deployment of fuel cells to power data centers, and the enthusiasm is continuing into this week as well.
Nuclear energy stocks have emerged as one of the most appealing alternative energy options for companies operating data centers, but the deal with Oracle suggests that Bloom Energy might have a robust new opportunity considering the massive amounts of capital that artificial intelligence (AI) companies are investing in data centers.
Another source of the market's ebullience is an analyst's auspicious outlook. Last Friday, UBS analyst Manav Gupta boosted the price target on Bloom to $51 from $29 due to the company's deal with Oracle.
Is Bloom ready to wilt, or is there still room to run?
While the Oracle deal and the analyst's revised price target are understandable reasons for shares to rise, it's important to acknowledge that there are more tangible reasons for buying the stock.
BE Revenue (Annual) data by YCharts.
Bloom Energy is growing both revenue and earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a hopeful sign that the company will succeed in a way that its peers have not. This makes Bloom Energy worth further investigation for fuel cell exposure.
Should you invest $1,000 in Bloom Energy right now?
Before you buy stock in Bloom Energy, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bloom Energy wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!*
Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 29, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
25 minutes ago
- CBC
Ontario-made alcohol gets largest tax cut in decades
Ontario's new alcohol tax cut, which is intended to support local producers, took effect last week. The province says the move will make the industry more competitive amid U.S. tariffs and growing economic pressures.
Globe and Mail
26 minutes ago
- Globe and Mail
CVRx (CVRX) Q2 Revenue Jumps 15%
Key Points Revenue (GAAP) rose 15% to $13.6 million, surpassing both company expectations and analyst estimates. Net loss narrowed on a per-share basis to $(0.57) (GAAP), primarily due to a higher share count despite a slight increase in overall losses. These 10 stocks could mint the next wave of millionaires › CVRx (NASDAQ:CVRX), a medical device innovator focused on heart failure therapy, released its second quarter 2025 earnings on August 4, 2025. The most important news was a Revenue (GAAP) increased to $13.6 million, up 15% year-over-year and above analyst expectations of $13.29 million (GAAP). The company also reported a net loss of $14.7 million, or $(0.57) per share (GAAP). While that loss widened slightly, the per-share figure (GAAP) improved due to an increased share count. The quarter reflected strong commercial progress for its Barostim neuromodulation device despite heavy investment in sales and marketing. Results slightly exceeded internal and external expectations, and management narrowed its revenue guidance to a range of $55.0 million to $57.0 million. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) $(0.57) $(0.52) $(0.65) 12.3% Revenue (GAAP) $13.6 million $13.29 million $11.8 million 15.1% Gross Profit $11.5 million N/A N/A Gross Margin 84% 84% 0% Net Loss $14.7 million $14.0 million -5.0% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About CVRx and Its Core Business CVRx (NASDAQ:CVRX) specializes in developing implantable medical devices for treating heart failure. Its leading product, Barostim, is a neuromodulation device—meaning it delivers targeted electrical pulses to nerves in the carotid artery to improve function of the autonomic nervous system. This system regulates key bodily functions, including blood pressure and heart rate. Barostim is designed to treat patients with heart failure with reduced ejection fraction (HFrEF), providing an option that avoids direct implantation in the heart. The company's commercial priorities are building deep adoption in centers with strong heart failure programs and expanding reimbursement pathways to improve access. Solid clinical evidence and reliable regulatory support have been the company's main success factors, along with educating physicians and patients on Barostim's benefits. Quarter Highlights and Key Developments During the period, total revenue (GAAP) reached $13.6 million, outpacing both the company's guides and Wall Street expectations by over 2%. U.S. heart failure revenue remained the largest contributor, climbing to $12.1 million, with units up to 387 from 339 in the prior year. U.S. sales overall were $12.2 million, also up 15% (GAAP). Across the Atlantic, European revenue grew 19% to $1.3 million (GAAP), but the number of European implant units declined from 63 to 61, signaling some softness in procedural volume despite improved pricing or product mix. Active implanting centers in the U.S. grew to 240, reflecting 13 new centers added in the U.S. during the quarter. U.S. sales territories also grew to 47, up from 45, while European territories held steady at five. U.S. revenue accounted for approximately 89.8% of total sales (GAAP), indicating the company's primary growth engine remains domestic. The company attributes revenue gains to both new account additions and greater utilization per center, while the slightly lower European volumes point to variability in adoption across geographies. Gross profit (GAAP) grew 16% from the prior year, maintaining a gross margin of 84%. On the expense side, research and development (R&D) spending declined 11% to $2.5 million, reflecting lower compensation as resources shifted toward commercial growth. Selling, general, and administrative (SG&A) costs (GAAP) increased 11% to $23.4 million, driven mainly by higher employee compensation, travel, and non-cash stock-based grants, with some relief from lower advertising costs. The higher SG&A, while outpaced by revenue growth, resulted in operating and net losses that remain substantial—operating loss (GAAP) at $14.4 million and net loss (GAAP) at $14.7 million. Multiple reimbursement milestones provided stability for Barostim's future. The Centers for Medicare & Medicaid Services (CMS) proposed to retain Barostim as a covered outpatient procedure at the $45,000 payment level, removing some uncertainty for hospitals and ensuring continued access. In addition, CMS proposed favorable physician payment levels of about $550 for new procedure coding effective in 2026. On the clinical front, highlighted real-world data presented at major cardiology conferences showed large reductions in heart failure hospital visits—down 85% for heart failure, 84% for cardiovascular causes, and 86% for all causes—after Barostim implantation, based on comparisons of hospital visits for 306 Barostim patients in the 12 months prior to implant and an average of almost two years post-implant. These real-world results have been well received by physicians and payers, which it views as an important driver of payer support and future uptake. Furthermore, the company is preparing a large pragmatic randomized controlled trial (RCT), potentially enrolling up to 2,000 patients, to further establish Barostim's efficacy, as discussed in recent management commentary. Although the timing and costs of that effort depend on regulatory approval and payer support, management sees it as a long-term enabler of broader use. The company finished the quarter with $95.0 million in cash and cash equivalents, down from $105.9 million at year end 2024. Net cash used for operations and investing was $8.0 million, showing some improvement from $10.2 million a year ago, but still indicating ongoing cash burn. Long-term debt remained steady at $49.4 million. Looking Ahead: Guidance and Watch Items For fiscal 2025, management narrowed its revenue guidance to $55.0–$57.0 million, tightening the prior range and signaling increased confidence from better visibility into commercial results. The company expects gross margin to remain high at 83–84%. Operating expenses are now projected at $96.0–$98.0 million, a slight increase at the midpoint, reflecting ongoing investments in sales and account growth. Revenue is expected in the range of $13.7–$14.7 million for the next quarter, suggesting continued double-digit revenue growth ahead, as evidenced by a 15% year-over-year increase. Areas to watch in the coming quarters include progress in adding new implanting centers, the effectiveness and productivity of the enlarged sales force, and movement toward scaling revenues faster than expenses. Investors will also monitor any shift in European procedure volumes, cash usage trends, and the company's progress on the planned large RCT, as this trial could both validate Barostim's utility and expand the addressable market if successful. CVRX does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
CTV News
an hour ago
- CTV News
Scott Moe speaks out against AI ‘deepfakes' of him circulating online
Saskatchewan Premier Scott Moe listens to a question from the media during the 2025 summer meetings of Canada's Premiers at Deerhurst Resort in Huntsville, Ont., on Wednesday, July 23, 2025. THE CANADIAN PRESS/Nathan Denette Saskatchewan Premier Scott Moe says his government is doing whatever it can to track down the creators of so-called 'deepfakes' of him and other prominent figures. Moe's likeness, including his voice, has been used in online video ads for cryptocurrency schemes that he says he would never endorse. The premier says on his official social media that some of the videos, which are created with artificial intelligence, feature him and others, including Prime Minister Mark Carney. Moe says his government is doing its best to find the people behind the videos, but adds it can be difficult to prevent the scams. It's not the first time Moe's image has been used to market the scams — he first acknowledged them in March. Saskatchewan's consumer watchdog has been issuing warnings about the impersonation scams and urges people not to send money to companies that aren't registered in the province. This report by The Canadian Press was first published Aug. 4, 2025.
